Edgewise Therapeutics, Inc. (EWTX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Edgewise Therapeutics, Inc.
Address
3415 Colorado Avenue
Boulder, CO 80303
United States of America (the)
Phone
303 735 8373
Website
Sector
Healthcare
Industry
Biotechnology
Employees
117
First IPO Date
March 26, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Kevin Koch | President, Chief Executive Officer & Director | 1.15M | 1960 |
| Badreddin Edris | Co-Founder & Independent Director | 55,000 | 1987 |
| Peter A. Thompson FACP | Co-Founder & Independent Chairman | 80,000 | 1960 |
| Michael Nofi | Chief Financial Officer | 97,700 | 1971 |
| Alan J. Russell | Co-Founder, Chief Scientific Officer & Director | 737,866 | 1970 |
| Joanne Donovan | Chief Medical Officer | 788,323 | 1957 |
| Behrad Derakhshan | Chief Operating Officer | 803,100 | 1980 |
| John R. Moore | General Counsel | 0 | 1964 |
Description
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
